Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2000, p. 1195-1199, Vol. 44, No. 5
Division of Infectious Diseases, Children's
Hospital and Health Center,1 and
Department of Pediatrics, University of
California,2 San Diego, California;
Section of Pediatric Clinical Pharmacology and Experimental
Therapeutics, Children's Mercy Hospital, and the Departments of
Pediatrics and Pharmacology, University of Missouri, Kansas City,
Missouri3; Division of Pediatric
Pharmacology and Critical Care, Rainbow Babies and Children's
Hospital, and Department of Pediatrics, School of Medicine, Case
Western Reserve University, Cleveland,
Ohio4; and Pfizer Central Research,
Groton, Connecticut5
Received 14 June 1999/Returned for modification 18 September
1999/Accepted 8 January 2000
The pharmacokinetics of trovafloxacin following administration of a
single intravenous dose of alatrofloxacin, equivalent to 4 mg of
trovafloxacin per kg of body weight, were determined in 6 infants (ages
3 to 12 months) and 14 children (ages, 2 to 12 years). There was rapid
conversion of alatrofloxacin to trovafloxacin, with an average ± standard deviation (SD) peak trovafloxacin concentration determined at
the end of the infusion of 4.3 ± 1.4 µg/ml. The primary
pharmacokinetic parameters (average ± SD) analyzed were volume of
distribution at steady state (1.6 ± 0.6 liters/kg), clearance
(151 ± 82 ml/h/kg), and half-life (9.8 ± 2.9 h). The drug was well tolerated by all children. There were no age-related differences in any of the pharmacokinetic parameters studied. Less than
5% of the administered dose was excreted in the urine over 24 h.
On the basis of the mean area under the concentration-time curve of
30.5 ± 10.1 µg · h/ml and the susceptibility (
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Pharmacokinetics of a Fluoronaphthyridone,
Trovafloxacin (CP 99,219), in Infants and Children following
Administration of a Single Intravenous Dose of
Alatrofloxacin
0.5
µg/ml) of common pediatric bacterial pathogens to trovafloxacin,
dosing of 4 mg/kg/day once or twice daily should be appropriate.
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Children's Hospital San Diego, 3020 Children's
Way MC 5041, San Diego, CA 92123. Phone: (858) 495-7785. Fax: (858) 571-3372. E-mail: jbradley{at}chsd.org.
Children's Hospital/University of California, San Diego; Arkansas
Children's Hospital, Little Rock; Rainbow Babies and Children's Hospital, Cleveland, Ohio; Children's Mercy Hospital, Kansas City, Mo.; Children's Hospital of Columbus, Columbus, Ohio; Louisiana State University Medical Center, Shreveport; and LeBonheur Children's Hospital, Memphis, Tenn.
Antimicrobial Agents and Chemotherapy, May 2000, p. 1195-1199, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Noreddin, A. M., Haynes, V. L., Zhanel, G. G.
(2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice
18: 432-443
[Abstract]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»